|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
WO1997040462A2
(en)
|
1996-04-19 |
1997-10-30 |
Spectra Biomedical, Inc. |
Correlating polymorphic forms with multiple phenotypes
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
AU9381598A
(en)
|
1997-09-10 |
1999-03-29 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
ES2265945T3
(es)
|
1999-06-04 |
2007-03-01 |
Consejo Superior De Investigaciones Cientificas |
Plantas, semillas y aceites de girasol con un contenido alto de oleico y alto de estearico.
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
WO2003015708A2
(en)
|
2001-08-18 |
2003-02-27 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
US20040180370A1
(en)
|
2003-01-27 |
2004-09-16 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
AU2004222436A1
(en)
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
|
|
TWI494102B
(zh)
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
US7276608B2
(en)
|
2003-07-11 |
2007-10-02 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
RU2330682C2
(ru)
|
2003-09-26 |
2008-08-10 |
Джапан Тобакко Инк. |
Способ ингибирования продуцирования остаточных липопротеинов
|
|
EP1670460B1
(en)
|
2003-10-10 |
2014-11-26 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
ES2284081T3
(es)
|
2003-12-19 |
2007-11-01 |
Bristol-Myers Squibb Company |
Heterociclos azabiciclicos como modulares de receptores canabinoides.
|
|
HRP20070241T3
(hr)
|
2003-12-19 |
2007-07-31 |
Bristol-Myers Squibb Company |
Azabiciklički heterocikli kao modulatori kanabinoid receptora
|
|
EP1735055A1
(en)
|
2004-03-30 |
2006-12-27 |
Sapphire Therapeutics, Inc. |
Method of reducing c-reactive protein using growth hormone secretagogues
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
BRPI0519602A2
(pt)
|
2004-12-18 |
2009-02-25 |
Bayer Healthcare Ag |
derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
|
|
US7375112B2
(en)
|
2005-01-05 |
2008-05-20 |
Medicure International Inc. |
Compounds and methods for regulating triglyceride levels
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
EP1901741B1
(en)
|
2005-07-01 |
2015-09-16 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a cetp inhibitor
|
|
RU2008119687A
(ru)
|
2005-10-21 |
2009-11-27 |
Новартис АГ (CH) |
Комбинации органических соединений
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
SG166829A1
(en)
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
US20070213274A1
(en)
*
|
2005-12-20 |
2007-09-13 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
CA2684067A1
(en)
|
2007-04-25 |
2008-11-06 |
F. Hoffmann-La Roche Ag |
Novel process for the preparation of acid chlorides
|
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
CN101952236B
(zh)
|
2008-04-04 |
2014-07-02 |
弗·哈夫曼-拉罗切有限公司 |
通过相应的环己烷羧酰胺衍生物制备环己烷羧酸衍生物的新工艺
|
|
AU2009231423B2
(en)
|
2008-04-04 |
2014-01-30 |
F. Hoffmann-La Roche Ag |
New process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
JP5325980B2
(ja)
|
2008-06-17 |
2013-10-23 |
エフ．ホフマン−ラ ロシュ アーゲー |
薬学的に活性なアミドの製造における中間体としての１−（２−エチル−ブチル）−シクロヘキサンカルボン酸エステル
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
WO2010056910A2
(en)
|
2008-11-12 |
2010-05-20 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
MX2011005304A
(es)
|
2008-12-08 |
2011-06-01 |
Hoffmann La Roche |
Administracion combinada de farmaco.
|
|
NZ720946A
(en)
|
2009-04-29 |
2017-09-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
TWI450896B
(zh)
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
EP2453926A4
(en)
|
2009-07-15 |
2015-08-12 |
Univ California |
PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING
|
|
AU2011237426A1
(en)
*
|
2010-04-07 |
2012-11-22 |
Isis Pharmaceuticals, Inc. |
Modulation of CETP expression
|
|
EP2598158A4
(en)
*
|
2010-07-28 |
2014-03-12 |
Inst Cardiologie Montreal |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
WO2012035017A1
(en)
|
2010-09-16 |
2012-03-22 |
F. Hoffmann-La Roche Ag |
New process
|
|
JP5676005B2
(ja)
|
2010-11-04 |
2015-02-25 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオアート及びクロスカルメロースナトリウムを含む組成物
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
BR112013014291A2
(pt)
|
2010-12-08 |
2016-09-20 |
Hoffmann La Roche |
formulação lipossômica de calcetrapib
|
|
EP2651882B1
(en)
|
2010-12-16 |
2018-11-14 |
F.Hoffmann-La Roche Ag |
Process for the preparation of aromatic thiol derivatives by hydrogenation of disulfides
|
|
WO2012112720A2
(en)
*
|
2011-02-15 |
2012-08-23 |
The Ohio University Research Foundaton |
Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
|
|
EP2675434A1
(en)
*
|
2011-02-17 |
2013-12-25 |
F.Hoffmann-La Roche Ag |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
JP5980900B2
(ja)
*
|
2011-04-08 |
2016-08-31 |
ゾラ バイオサイエンシーズ オサケ ユキチュア |
スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
KR20140059170A
(ko)
*
|
2011-04-29 |
2014-05-15 |
칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 |
역 콜레스테롤 수송을 지지하는 ｈｄｌ의 능력을 평가하기 위한 조성물 및 방법
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
AR090259A1
(es)
|
2012-03-06 |
2014-10-29 |
Boehringer Ingelheim Int |
Inhibidores de benzodioxano de la produccion de leucotrieno para terapia de combinacion
|
|
MX2014012349A
(es)
|
2012-04-30 |
2015-01-12 |
Hoffmann La Roche |
Nueva formulacion.
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
PT2978859T
(pt)
*
|
2013-03-27 |
2018-10-04 |
Hoffmann La Roche |
Marcadores genéticos para previsão da capacidade de resposta à terapêutica
|
|
MX2016005505A
(es)
|
2013-12-19 |
2016-07-22 |
Hoffmann La Roche |
Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
RU2703192C2
(ru)
|
2014-07-30 |
2019-10-15 |
Ф. Хоффманн-Ля Рош Аг |
Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
|
|
WO2019043018A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
|
|
MX2021001520A
(es)
|
2018-08-09 |
2021-05-27 |
Dalcor Pharma Uk Ltd Leatherhead Zug Branch |
Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
|